Preoperative analysis of 11q loss using circulating tumor-released DNA in serum: a novel diagnostic tool for therapy stratification of neuroblastoma

Shigeki Yagyu; Tomoko Iehara; Takahiro Gotoh; Mitsuru Miyachi; Yoshiki Katsumi; Ken Kikuchi; Kunihiko Tsuchiya; Shinya Osone; Hiroshi Kuroda; Tohru Sugimoto; Tadashi Sawada; Hajime Hosoi

doi:10.1016/j.canlet.2011.05.032

Preoperative analysis of 11q loss using circulating tumor-released DNA in serum: a novel diagnostic tool for therapy stratification of neuroblastoma

Cancer Lett. 2011 Oct 28;309(2):185-9. doi: 10.1016/j.canlet.2011.05.032. Epub 2011 Jun 24.

Authors

Shigeki Yagyu¹, Tomoko Iehara, Takahiro Gotoh, Mitsuru Miyachi, Yoshiki Katsumi, Ken Kikuchi, Kunihiko Tsuchiya, Shinya Osone, Hiroshi Kuroda, Tohru Sugimoto, Tadashi Sawada, Hajime Hosoi

Affiliation

¹ Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

PMID: 21726937
DOI: 10.1016/j.canlet.2011.05.032

Abstract

Allelic deletion of the long arm of chromosome 11 (11q loss) is closely associated with the prognosis of neuroblastoma (NB). Here we examined 11q loss using tumor-released DNA fragments in the sera of 24 cases. The allelic intensity score of a panel of polymorphic markers in 11q23 in serum DNA was significantly different between the 11q loss-positive group and the11q loss-negative group. The 11q loss-positive and -negative groups did not overlap when a cut-off value of 0.5 was chosen for the allelic intensity score. Our serum-based 11q loss analysis could predict the allelic status of 11q in tumors.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Alleles
Base Sequence
Child, Preschool
Chromosome Deletion*
Chromosomes, Human, Pair 11 / genetics*
DNA / blood*
DNA Fragmentation
Humans
Infant
Microsatellite Repeats / genetics
Neuroblastoma / diagnosis*
Neuroblastoma / genetics
Neuroblastoma / therapy
Prognosis
Sequence Deletion*

Substances

DNA